close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.190 -0.130 (-3.01%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
News headline image
Where Will Recursion Pharmaceuticals Be in 5 Years? ↗
A lot is riding on whether its platform is valuable, or vaporware. 
Via The Motley Fool
News headline image
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals ↗
 
Via Benzinga
News headline image
Forecasting The Future: 4 Analyst Projections For Recursion Pharmaceuticals ↗
 
Via Benzinga
News headline image
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential ↗
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
News headline image
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024 ↗
Through opportunity for growth and strong financial performance, these three Cathie Wood stocks could provide generous returns. 
Via InvestorPlace
News headline image
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD ↗
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock ↗
On Thursday, Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc. (NASDAQ:COIN), Palantir Technologies Inc. (NYSE:PLTR), and Nvidia Corp. 
Via Benzinga
News headline image
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. ↗
Recursion is playing the long game with its AI-focused approach to drug discovery and development. 
Via The Motley Fool
News headline image
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation ↗
They might not be profitable yet, but they're swinging for the fences. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AI Surge Ending: Only One Category Was Up This Week ↗
Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy? ↗
This stock's upside is huge, but so is its downside. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March ↗
No AI category went down in February, but 3 did in March - confirming my comment last week that 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares ↗
 
Via Benzinga
News headline image
Recursion Publishes Annual Environmental, Social and Governance Report
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships ↗
Nvidia announces partnerships with J&J and GE Healthcare to integrate generative AI into surgery and medical imaging at GTC AI conference. Analysts see potential for revenue growth outside tech sector.... 
Via Benzinga
Topics Artificial Intelligence
News headline image
New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence ↗
 
Via Benzinga
News headline image
Nvidia's Secret Weapon Is Not Just Chips But Investing $1.5B In AI's Rising Stars: Report Unveils CEO Jensen Huang's 10-Year Vision ↗
Additionally, the investments help Nvidia "build out the future ecosystem of businesses that depend on its technology" even as rivals are trying to break into the chipmaker's dominance. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
News headline image
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst ↗
The company just made a provocative move in one of its collaborations. 
Via The Motley Fool
News headline image
The Top 7 Small-Cap Stocks to Buy in March 2024 ↗
These top small-cap stocks to buy are set for a strong 2024 as reduced inflation increases their growth prospects. 
Via InvestorPlace
Topics Economy
News headline image
The Top 3 Healthcare Stocks to Buy on Weakness in 2024 ↗
Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy. 
Via InvestorPlace
News headline image
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD ↗
Grand View Research says the global 
Via Talk Markets
News headline image
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? ↗
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks. 
Via InvestorPlace
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today